How often esophageal cancer spreads to the subcarinal (107) lymph node
A Prospective Observational Study of Subcarinal Lymph Node Metastasis in Patients With Esophageal Cancer
This study will try to find how often esophageal squamous cell carcinoma spreads to the subcarinal (107) lymph node and which patients are more likely to have that spread when they undergo esophagectomy.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 1100 (estimated) |
| Ages | 20 Years to 85 Years |
| Sex | All |
| Sponsor | Fudan University Academic / other |
| Drugs / interventions | chemotherapy, immunotherapy |
| Locations | 1 site (Shanghai, Shanghai Municipality) |
| Trial ID | NCT07165184 on ClinicalTrials.gov |
What this trial studies
This is a prospective observational study at Fudan University Shanghai Cancer Center enrolling patients with esophageal squamous cell carcinoma (cT1-4a N0/+ M0) who are planned for esophagectomy. Surgeons will document whether subcarinal (station 107) lymph nodes contain cancer and collect clinical and pathological data to identify risk factors for metastasis. The study aims to quantify the incidence of subcarinal metastasis and examine its relation to postoperative respiratory complications and long-term outcomes. The goal is to provide evidence to guide whether routine removal of subcarinal nodes is necessary given potential harms from dissection.
Who should consider this trial
Good fit: Ideal candidates are adults with esophageal squamous cell carcinoma staged cT1-4a N0/+ M0 who are medically fit for esophagectomy and have no history of other malignancies.
Not a fit: Patients with cervical (neck) esophageal cancer, non-squamous histology, distant metastases, or who are too frail for surgery are unlikely to benefit from this study's findings.
Why it matters
Potential benefit: If successful, the results could help surgeons avoid unnecessary subcarinal node removal, reducing postoperative respiratory complications while maintaining cancer control.
How similar studies have performed: Retrospective data have reported a low (~2%) rate of subcarinal metastasis and mixed results on the benefit of extended nodal dissection, while prospective confirmation is limited.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * patients with esophageal squamous cell carcinoma * clinical staging: cT1-4a N0/+ M0. * no history of other malignancy. Exclusion Criteria: * esophageal cancer in the neck * poor physical status to have esophagectomy.
Where this trial is running
Shanghai, Shanghai Municipality
- Fudan University Shanghai Cancer Center — Shanghai, Shanghai Municipality, China (Recruiting)
Study contacts
- Study coordinator: Bin Li, MD
- Email: lb0256327@hotmail.com
- Phone: 086-021-64175590-82500
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.